News

In preparation for the American Society of Retina Specialist (ASRS) annual meeting being held in Long Beach, California, Modern Retina spoke with Gaurav Shah MD, FASRS, Program Chair of the 2025 event.

The companies will focus their joint effort on extended-release therapies for ocular disease

Re-Vana Therapeutics and Boehringer Ingelheim forge a $1 billion partnership to develop innovative extended-release therapies for eye diseases, enhancing patient care.

In preparation for the American Society of Retina Specialist (ASRS) annual meeting being held in Long Beach, California, Ophthalmology spoke with Gaurav Shah MD, FASRS, Program Chair of the 2025 event.

The annual Best Hospitals report from US News & World Report compares more than 4500 hospitals across 15 specialties and 22 procedures and conditions.

Optical coherence tomography may help identify patients at risk of cardiovascular disease before coronary angiography

LENZ Therapeutics previously licensed Greater China rights to CORXEL for the development and commercialization of LNZ100 in April 2022.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

Catch up on this week's highlights in retina.

Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa

A recent study reveals that many Americans neglect eye care due to cost and urgency misconceptions, despite the significant impact on daily life.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

Rhino-orbital-cerebral mucormycosis, a life-threatening fungal infection, typically occurs in patients with diabetes

Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa.

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests.

Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa

Vonaprument has received fast track designation from the US Food and Drug Administration.

KIO-104 is for the treatment of a wide range of ocular diseases, including ocular inflammation, uveitis, age-related macular degeneration (AMD), and complications as a result of refractive surgery.

Australian researchers highlighted the overlooked ocular risks surfers and divers face from UV and blue light exposure.

Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.

At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization in ophthalmology research.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.